Cytokines in Hemopoiesis, Oncology, and AIDS II

and Overview.- Cytokine Interactions in Hematopoiesis: An Introduction and Overview.- The Role of Colony-Stimulating Factors in Infection.- Physicochemical and Pharmacological Characterization of Interleukin-4: Implications for Clinical Utility.- Interleukin-10: An Overview.- Preclinical and In Vitro Data.- Colony-Stimulating Factors and Hematopoietic Cells.- In Vitro Modifications Induced by Granulocyte-Macrophage Colony-Stimulating Factor in Human Long-Term Bone Marrow Cultures.- The Addition of Granulocyte-Macrophage Colony-Stimulating Factor to Normal Bone Marrow Enhances Cell Cycle and Clonogenicity Irrespective of Cryopreservation.- Effect of Biological Response Modifiers on Human Bone Marrow Progenitor Cells in Human Immunodeficiency Virus Infection.- Plasma Erythropoietic Activity and Hemopoiesis in Murine Postnatal Ontogenesis.- In Vitro Modulation of Granulocyte-Macrophage Colony-Stimulating Factor Induced Granulocyte Surface Markers by Pentoxifylline.- Myeloperoxidase: Gene Demethylation and Expression in Acute Myeloid Leukemias.- Transduction of Neo+ Gene into Stromal Precursor Cells of Hematopoietic Microenvironment by Retroviral Gene Transfer.- Cytokines in Tumor Development and Suppression.- Cytokine Involvement in Tumor Development and Tumor Suppression.- Modulation of Growth of a Xenotransplanted Human Colon Adenocarcinoma Cell Line in Nude Mice Under the Influence of Systemic Recombinant Human GM-CSF.- Influence of Interleukin-3, Granulocyte-Macrophage Colony-Stimulating Factor, and Granulocyte Colony-Stimulating Factor on the Proliferation of Human and Murine Urothelial Tumor Cell Lines.- Different Cytokines with Autocrine and Immunosuppressive Activities are Secreted by a Small-Cell Lung Cancer Cell Line.- Effects of Recombinant Human Erythropoietin on Clonogenic Growth of Primary Human Tumor Specimens in Vitro.- Growth-Modulation Effects of Interleukin-1?, Interleukin-1?, and Macrophage Colony-Stimulating Factor in Clonogenic Tumor Cells In Vitro.- Effects of Interleukin-4, Interleukin-5, and Interleukin-7 on Clonogenic Growth of Primary Human Tumors In Vitro.- Effects of Interleukin-6 on Soft Agar Colony Formation of Primary Solid Tumor Specimens.- Chronic Lymphocytic Leukemia B Cells Express and Secrete Significant Amounts of Transforming Growth Factor-?.- In Vitro Tumor Necrosis Factor and Interleukin-1 Production in Patients with Chronic Lymphocytic Leukemia.- Effects of Tumor Necrosis Factor-? on Acute Myeloid Leukemia Cells Measured by Flow Cytometric Detection of Bromodeoxyuridine Incorporation.- Mitogenic Effect of Human Stem Cell Factor Alone or in Combination with G-CSF, GM-CSF, and IL-3 on Fresh Leukemic Blasts from Patients with Stem Cell Factor Receptor-Positive Acute Myeloid Leukemia.- Effect of Interleukin-3 in Human Hematopoietic Progenitor and Precursor Cells in Patients with Myelodysplastic Syndromes.- Differential Response of Cytogenetically Abnormal Cell Clones in Myelodysplastic Syndromes to Cytokines In Vitro.- The In Vitro Effect of Interferon-? on Chronic Myeloid Leukemia Cells.- Simultaneous Measurement of Immunophenotype and DNA Content of Bone Marrow Cells.- Cytokines in Hodgkin’s Disease.- The Expression Pattern of Cytokine Genes and Cytokine Receptors by Hodgkin’s Disease-Derived Cell Lines HDLM-2 and KM-H2 Resembles That of Activated T Cells.- Cytokine Receptors.- Tumor Necrosis Factor and Lymphotoxin-Induced Signal Pathways.- Tumor Necrosis Factor Receptor Expression on Human Normal and Malignant B Lymphocytes: Anti-75-kDa Tumor Necrosis Factor Receptor Antibody Inhibits B-Cell Proliferation.- Detection of Point Mutations Within the Macrophage Colony-Stimulating Factor Receptor Gene in Myelodysplastic Syndromes and Acute Myelomonocytic Leukemias.- Interleukin-2 Activates Nuclear Factor kB Binding Activity and Autoregulates Transcriptional Activity of its Own Receptor Gene by Normal Human Monocytes Engaging Nuclear Factor kB.- Interleukin-4 Downregulates Expression of c-kit mRNA and YB5. B8 Antigen (Stem Cell Factor Receptor) in Human Myeloid/Mast Cell Progenitor Cells.- Biochemical Characterization and Regulation of Expression of the Binding Protein for the Granulocyte Colony-Stimulating Factor on Leukemia Cells.- Tetrahydrobiopterin is a Feedback Modulator of the Interleukin-2 Receptor Complex: Manifestations and Mechanisms.- Receptor Cross-Talk: Protein Kinase C Dependent Down-Modulation of the Colony-Stimulating Factor-1 Receptor upon Activation with Interferon-?/Lipopolysaccharide.- The Interleukin-2 Receptor (CD25 and p75) in Human Monocytes and Macrophages.- Combinations of Cytokines and Cytotoxic Drugs In Vitro.- Synergism of Hematopoietic Cytokines and Cytosine Arabinoside in the Treatment of Acute Myelogenous Leukemia: Experimental Rationales.- Effects of Recombinant Human Cytokines on Cytarabine Activity in K562 Human Myeloid Leukemia Cells.- Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Increases DNA Polymerase Activity in Acute Myeloid Leukemia Blasts In Vitro and In Vivo.- Kinetic and Genetic Resistance in Acute Leukemia.- Combination of Hematopoietic Growth Factors Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-1 Reduces Toxicity of Cisplatin, Carboplatin, and Azidothymidine on Normal Human and Murine Hematopoietic Progenitors.- The Susceptibility of Human Leukemia Cells to Allogeneic and Autologous Lymphokine-Activated Killer Cells and Augmentation of the Susceptibility by Exposure of Target Cells to Cytotoxic Drugs In Vitro and In Vivo.- Other Effects and Factors.- CD16 Stimulation Induces Stronger Accumulation of Cytokine mRNA in Natural Killer Cells than in Non-MHC-Restricted T Lymphocytes.- Influence of Chemo- and Radiotherapy on Interleukin-1 Production by Mononuclear Cells of Children with Hematological Malignancies.- Pokeweed Mitogen Induction of Interleukin-2 and Interleukin-6 in Mononuclear Cells: An Alternative Approach to the Combined Phytohemagglutinin/Phorbol Myristrate Acetate Stimulation In Vitro.- Immunomodulatory Activity of Hexadecylphosphocholine: Hexadecylphosphochloine-Meidated Enhancement of T-Cell Response.- Long-Term Culture and Expansion of Adherent Lymphokine-Activated Killer Cells.- Bomirski Ab Melanoma as a Model of Tumor-Induced Cachexia.- Preclinical Evaluation of Cytokines in Animal Models.- In Vivo Effects of Interleukin-6 and Leukemia Inhibitory Factor on Thrombopoiesis in Primates.- In Vivo Synergism of Interleukin-3 and Interleukin-6 on Thrombopoiesis in Primates.- Clinical Data.- Cytokines and Their Soluble Receptors in the Serum.- Increased Erythropoietin Response After Treatment with Cisplatin, Etoposid, and Bleomycin in Patients with Testicular Cancer.- Systemic Release of Tumor Necrosis Factor Alpha in Human Allogeneic Bone Marrow Transplantation: Clinical Risk Factors, Prognostic Significance, and Therapeutic Approaches.- Sequential Release of Tumor Necrosis Factor Alpha and Tumor Necrosis Factor Receptors in Complications of Human Bone Marrow Transplantation.- Tumor Necrosis Factor ? in the Course of Allogeneic and Autologous Bone Marrow Transplantation.- Differences in Stimulated Cytokine Release Between Sleep and Sleep Deprivation.- Interleukin-5 Expressing Allergen-Specific T Cells in Patients with House Dust Mite Sensitization: Analysis at a Clonal Level.- G-CSF.- Issues in the Clinical Development of Recombinant Methionyl Human Granulocyte Colony-Stimulating Factor: A Review.- The Use of Recombinant Methionyl Human Granulocyte Colony-Stimulating Factor Following High-Dose Chemotherapy and Autologous Bone Marrow Transplantation.- Recombinant Methionyl Human Granulocyte Colony-Stimulating Factor in High-Risk Non-Hodgkin’s Lymphoma Treated with VIM and CHOP: Preliminary Results of a Phase I/II Study.- Granulocyte Colony-Stimulating Factor in the Therapy of Myeloid Leukemia.- Granulocyte Colony-Stimulating Factor Corrects Neutropenia and Associated Clinical Symptoms in Children with Severe Congenital Neutropenia.- Severe Reversible Renal Failure Induced by Recombinant Human Granulocyte Colony-Stimulating Factor in a Child with Chronic Acquired Agranulocytosis.- In Vitro Functions of Granulocyte Colony-Stimulating Factor Induced Neutrophils.- Impaired Calcium Mobilization and Abnormalities in Microfilamentous Cytoskeletal Organization in Granulocyte Colony-Stimulating Factor Induced Neutrophils from Patients with Severe Congenital Neutropenia.- GM-CSF.- Treatment of Poor-Risk Neuroblastoma with Intensive Chemotherapy and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor.- Treatment of Relapsed Acute Myeloid Leukemia with Granulocyte-Macrophage Colony-Stimulating Factor and Intensive Chemotherapy.- Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Aplastic Anemia: A Phase I/II Trial Emphasis on Very Severe Neutropenia and Active Infection.- Successful Third Bone Marrow Transplantation for Severe Aplastic Anémia: Possible In Vivo Synergism of Granulocyte-Macrophage Colony-Stimulating Factor and Erythropoietin.- Stimulation of Peripheral Blood Progenitor Cells by Chemotherapy and Granulocyte-Macrophage Colony-Stimulating Factor in Lymphoproliferative Diseases.- Autologous Transplantation of Blood Stem Cells Mobilized with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Subsequent to Chemotherapy for Relapsed Hodgkin’s Disease.- Immunological Characterization of Blood Stem Cell Autografts Collected Under Administration of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor.- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Serum Levels of Soluble CD25, CD8, an CD4 in Patients with Hodgkin’s Disease in Sensitive Relapse.- Migration of Neutrophils to the Oral Mucosa During Treatment with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor.- Interleukin-1.- Clinical Trials of Interleukin-1?.- Interleukin-3.- Clinical Evaluation of Interleukin-3.- Response to Interleukin-3 Treatment in Graft Failure After Bone Marrow Transplantation.- Erythropoietin.- Erythropietin Treatment in Allogeneic Bone Marrow Transplantation: A Prospective and Randomized Trial.- In Vivo Effects of Recombinant Human Erythropoietin on Circulating CD34+ Cells of Uremic Patients.- Interferons.- Interferon-?-2b in the Treatment of Chronic Myeloid Leukemia.- Interferon-?-2a in the Treatment of Chronic Myeloid Leukemia: Results of the Spanish Group on Interferon-?-2a in CML.- Complex Karyotype Evolution Influenced by Interferon Therapy in a Case of Ph-Positive Chronic Myeloid Leukemia.- Treatment of Primary and Relapsed Angioimmunoblastic-Type T-Cell Lymphoma with Recombinant Human Interferon-?.- New Aspects in the Treatment of Human Immunodeficiency Virus Related Koposi’s Sarcoma with High-Dose Intralesional Recombinant Interferon ? 2b.- Combination of Interferon-? and Standard Chemotherapy in Advanced Malignancies.- A 21-kDa Protein as Marker in the Course of Chemotherapy Combined with Cytokines: Interferon-? or Granulocyte-Macrophase Colony-Stimulating Factor.- Treatment with Human Recombinant Tumor Necrosis Factor-? of Patients with Acute Myeloid Leukemia and Chronic Myeloid Leukemia in its Accelerated or Blastic Phase.- Outpatient Therapy of Advanced Malignancies Using Recombinant Interleukin-2 and Recombinant Inteferon-? With or Without Chemotherapy.- Treatment of Metastatic Melanoma with Interferon-? and Interleukin-2: Significant Improvement with a New-Dosing Schedule.- Sequential Chemoimmunotherapy in the Treatment of Metastatic Melanoma.- Interleukin-2 in Combination with Dacarbazine in the Treatment for Malignant Melanoma.- Characterization of CD3+ and CD56+ Lymphocyte Subsets in Melanoma Patients After In Vivo Recombinant Interleukin-2 Administration.- Low-Dose Subcutaneous Interleukin-2 in Human Multiple Myeloma: Current Results of a Phase I/II Pilot Study.- Tolerance and Biological Activity of Bolus Administration of Increasing Doses of Glycosylated Recombinant Interleukin-2 (SR 29009) in Patients with Hematological Malignancy.- Treatment of Relapsed Acute Leukemias with Systemic Recombinant Interleukin-2 (RU 49637).- Use of Recombinant Interleukin-2 (RU 49637) After Autologous Bone Marrow Transplantation in Patients with Hematological Disease: Phase I–II Study.- Phase I/II Trial with Low-Dose Interleukin-2 and Interferon-Gamma in Children with High-Risk Leukemia and Non-Hodgkin’s Lymphoma After Autologous Bone Marrow Transplantation.- Autologous Bone Marrow Transplantation with 10-Day-Cultured Bone Marrow Activated by Interleukin-2 in Two Patients with Acute Lymphoblastic Leukemia.- Antibody Formation in Cancer Patients Treated with Recombinant Interleukin-2 Alone or in Combination with Interferon-? 2b.